$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
How long does a box of bedaquiline last?
2026-02-01 22:25:32
Check Details
Osimertinib Indian version price and authenticity identification guide in 2024
2026-02-01 22:25:32
Check Details
Detailed explanation of the efficacy and side effects of osimertinib in EGFR T790M mutated lung cancer
2026-02-01 22:25:32
Check Details
Which company produces osimertinib, and how can patients ensure that they purchase genuine drugs?
2026-02-01 22:25:32
Check Details
What are the functions and effects of tepotinib? How to use this medicine correctly?
2026-02-01 22:25:32
Check Details
Is the quality of the Laos-ASEAN version of tepotinib generic drug reliable? What is the current selling price per box?
2026-02-01 22:25:32
Check Details
What side effects does Tepotinib cause? How to effectively deal with these adverse reactions?
2026-02-01 22:25:32
Check Details
The three most taboo foods for Venetocla/Venetoc
2026-02-01 22:25:32
Check Details
Is the Lao version of Venetocla/Venetocla genuine?
2026-02-01 22:25:32
Check Details
Is it true that venetoclax/venetoclax heals itself?
2026-02-01 22:25:32
Check Details
How long does it take to take Venetoclax/Venetoclax?
2026-02-01 22:25:32
Check Details
How long can one live with prostate cancer?
2026-02-01 22:25:32
Check Details
1
2
...
1190
1191
1192
1193
1194
1195
1196
...
10224
10225
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
2
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring
3
Encorafenib (Braftovi): Comprehensive Guide to BRAF V600 Inhibitor Indications, Dose Regimens by Tumor Type, and Administration Requirements
4
Tazemetostat: Mechanism, Standard Dosing, and the 2026 Global Withdrawal of the First-in-Class EZH2 Inhibitor
5
FDA Approves Orzeyful, the World's First Orexin Receptor Agonist for Narcolepsy Type 1, Ushering in a New Era of Root-Cause Therapy
6
Alpelisib vs Inavolisib: How to Choose Between Two PI3Kα Inhibitors in PIK3CA-Mutated Breast Cancer
7
Selumetinib: The First MEK1/2 Inhibitor Approved for Inoperable Plexiform Neurofibromas in NF1
8
FIGHT-302 Phase 3 Trial: First-Line Pemigatinib Significantly Improves PFS Over Chemotherapy in FGFR2-Rearranged Cholangiocarcinoma
9
Selpercatinib Dosing Guide: Weight-Based Precision Targeting for RET-Driven Tumors
10
Mitotane Side Effects: Understanding Key Risks in Adrenocortical Carcinoma Therapy
11
Ponatinib: A Third-Generation TKI Targeting BCR::ABL1 to Overcome Leukemia Drug Resistance
12
Axitinib: Indications, Mechanism of Action & Key Safety Warnings